Christopher S Henney - Net Worth and Insider Trading
Christopher S Henney Net Worth
The estimated net worth of Christopher S Henney is at least $501,000 dollars as of 2024-04-24. Christopher S Henney is the Director of Cascadian Therapeutics Inc and owns about 50,000 shares of Cascadian Therapeutics Inc (CASC) stock worth over $501,000. Christopher S Henney is the Director of Prothena Corp PLC and owns about 0 shares of Prothena Corp PLC (PRTA) stock worth over $0. Christopher S Henney is also the Director of Bio-Techne Corp and owns about 0 shares of Bio-Techne Corp (TECH) stock worth over $0. Details can be seen in Christopher S Henney's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Christopher S Henney has not made any transactions after 2021-07-14 and currently still holds the listed stock(s).
Transaction Summary of Christopher S Henney
Christopher S Henney Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Christopher S Henney owns 7 companies in total, including Cyclacel Pharmaceuticals Inc (CYCC) , Prothena Corp PLC (PRTA) , and Cascadian Therapeutics Inc (CASC) among others .
Click here to see the complete history of Christopher S Henney’s form 4 insider trades.
Insider Ownership Summary of Christopher S Henney
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CYCC | Cyclacel Pharmaceuticals Inc | 2006-06-14 | director |
| PRTA | Prothena Corp PLC | 2021-07-14 | director |
| CASC | Cascadian Therapeutics Inc | 2018-03-09 | director |
| ANTH | Anthera Pharmaceuticals Inc | 2018-01-05 | director |
| MYMX | Mymetics Corp | 2012-03-23 | director |
| SRPT | Sarepta Therapeutics Inc | 2009-03-31 | director |
| TECH | Bio-Techne Corp | 2004-09-17 | director |
Christopher S Henney Latest Holdings Summary
Christopher S Henney currently owns a total of 3 stocks. Among these stocks, Christopher S Henney owns 50,000 shares of Cascadian Therapeutics Inc (CASC) as of January 30, 2017, with a value of $501,000 and a weighting of 100%. Christopher S Henney owns 0 shares of Prothena Corp PLC (PRTA) as of July 14, 2021, with a value of $0 and a weighting of 0%. Christopher S Henney also owns 0 shares of Bio-Techne Corp (TECH) as of September 17, 2004, with a value of $0 and a weighting of 0%.
Latest Holdings of Christopher S Henney
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CASC | Cascadian Therapeutics Inc | 2017-01-30 | 50,000 | 10.02 | 501,000 |
| PRTA | Prothena Corp PLC | 2021-07-14 | 0 | 20.56 | 0 |
| TECH | Bio-Techne Corp | 2004-09-17 | 0 | 63.52 | 0 |
Holding Weightings of Christopher S Henney
Christopher S Henney Form 4 Trading Tracker
According to the SEC Form 4 filings, Christopher S Henney has made a total of 0 transactions in Cascadian Therapeutics Inc (CASC) over the past 5 years. The most-recent trade in Cascadian Therapeutics Inc is the acquisition of 25,324 shares on January 30, 2017, which cost Christopher S Henney around $104,082.
According to the SEC Form 4 filings, Christopher S Henney has made a total of 3 transactions in Prothena Corp PLC (PRTA) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Prothena Corp PLC is the sale of 11,108 shares on July 14, 2021, which brought Christopher S Henney around $616,050.
According to the SEC Form 4 filings, Christopher S Henney has made a total of 0 transactions in Bio-Techne Corp (TECH) over the past 5 years. The most-recent trade in Bio-Techne Corp is the sale of 12,000 shares on September 17, 2004, which brought Christopher S Henney around $122,280.
Insider Trading History of Christopher S Henney
- 1
Christopher S Henney Trading Performance
GuruFocus tracks the stock performance after each of Christopher S Henney's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher S Henney is 1.43%. GuruFocus also compares Christopher S Henney's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher S Henney within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Christopher S Henney's insider trading performs compared to the benchmark.
Performance of Christopher S Henney
Average Return
40.81%
Outperforming Transactions
100%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.72 | 1.43 | -5.25 | 40.81 | ||
| Relative Return to S&P 500(%) | -3.71 | -3.1 | -13.63 | 17.07 |
Christopher S Henney Ownership Network
Ownership Network List of Christopher S Henney
Ownership Network Relation of Christopher S Henney
Christopher S Henney Owned Company Details
What does Cyclacel Pharmaceuticals Inc do?
Who are the key executives at Cyclacel Pharmaceuticals Inc?
Christopher S Henney is the director of Cyclacel Pharmaceuticals Inc. Other key executives at Cyclacel Pharmaceuticals Inc include director & President & C.E.O. Spiro Rombotis , director & E.V.P. & Finance & C.O.O. Paul Mcbarron , and Chief Medical Officer Mark Kirschbaum .
Cyclacel Pharmaceuticals Inc (CYCC) Insider Trades Summary
Over the past 18 months, Christopher S Henney made no insider transaction in Cyclacel Pharmaceuticals Inc (CYCC). Other recent insider transactions involving Cyclacel Pharmaceuticals Inc (CYCC) include a net purchase of 6,070 shares made by Spiro Rombotis , and a net purchase of 1,886 shares made by Paul Mcbarron .
In summary, during the past 3 months, insiders sold 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) were sold and 7,956 shares were bought by its insiders, resulting in a net purchase of 7,956 shares.
Cyclacel Pharmaceuticals Inc (CYCC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cyclacel Pharmaceuticals Inc Insider Transactions
Christopher S Henney Mailing Address
Above is the net worth, insider trading, and ownership report for Christopher S Henney. You might contact Christopher S Henney via mailing address: 10505 Roselle Street, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
